FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Anish Bhatnagar
2. Issuer Name and Ticker or Trading Symbol

SOLENO THERAPEUTICS INC [ SLNO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

203 REDWOOD SHORES PKWY, STE 500
3. Date of Earliest Transaction (MM/DD/YYYY)

1/23/2020
(Street)

REDWOOD CITY, CA 94065
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/23/2020  A  381000 (1)A$3.35 381000 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) The reported securities are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of SLNO common stock. The RSUs shall start vesting on January 23, 2020 and shall vest twenty-five percent (25%) on each year anniversary, such that twenty-five percent (25%) shall vest on January 22, 2021, twenty-five percent (25%) shall vest on January 22, 2022, twenty-five percent (25%) shall vest on January 22, 2023 and twenty-five percent (25%) shall vest on January 22, 2024, subject to the Reporting Person's continued service on each such date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Anish Bhatnagar
203 REDWOOD SHORES PKWY, STE 500
REDWOOD CITY, CA 94065


Chief Executive Officer

Signatures
/s/ Anish Bhatnagar1/23/2020
**Signature of Reporting PersonDate

Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Soleno Therapeutics Charts.
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Soleno Therapeutics Charts.